Total Payments
$5,346
2024 Payments
$374.82
Companies
55
Transactions
258
Medicare Patients
1,748
Medicare Billing
$145,598
Payment Breakdown by Category
Food & Beverage$4,628 (86.6%)
Education$718.10 (13.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,628 | 241 | 86.6% |
| Education | $718.10 | 17 | 13.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $618.81 | 28 | $0 (2024) |
| Astellas Pharma US Inc | $509.68 | 9 | $0 (2024) |
| Genentech USA, Inc. | $460.45 | 27 | $0 (2023) |
| PFIZER INC. | $419.42 | 31 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $372.87 | 19 | $0 (2024) |
| Merck Sharp & Dohme LLC | $276.96 | 14 | $0 (2024) |
| Amgen Inc. | $267.31 | 14 | $0 (2023) |
| Janssen Biotech, Inc. | $265.54 | 14 | $0 (2023) |
| Celgene Corporation | $188.44 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $187.89 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $374.82 | 16 | Celgene Corporation ($45.56) |
| 2023 | $1,452 | 69 | Novartis Pharmaceuticals Corporation ($168.13) |
| 2022 | $1,008 | 45 | Astellas Pharma US Inc ($181.98) |
| 2021 | $277.43 | 15 | Amgen Inc. ($65.48) |
| 2020 | $201.28 | 10 | Genentech USA, Inc. ($41.44) |
| 2019 | $1,292 | 71 | Genentech USA, Inc. ($274.94) |
| 2018 | $258.03 | 11 | Astellas Pharma US Inc ($99.99) |
| 2017 | $482.90 | 21 | Pharmacyclics LLC, An AbbVie Company ($98.03) |
All Payment Transactions
258 individual payment records from CMS Open Payments — Page 2 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $29.70 | General |
| Category: Oncology | ||||||
| 10/05/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG, LYNPARZA | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2023 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug), SCEMBLIX | Food and Beverage | In-kind items and services | $33.55 | General |
| Category: Oncology | ||||||
| 09/19/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: Oncology | ||||||
| 09/12/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug), KISQALI | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: Oncology | ||||||
| 08/16/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug), KISQALI | Food and Beverage | In-kind items and services | $23.67 | General |
| Category: Oncology | ||||||
| 08/11/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: ONCOLOGY | ||||||
| 08/04/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.28 | General |
| Category: ONCOLOGY | ||||||
| 08/03/2023 | Genentech USA, Inc. | Perjeta (Biological), Phesgo | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: BioOncology | ||||||
| 08/03/2023 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $22.90 | General |
| Category: Oncology | ||||||
| 07/27/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $21.88 | General |
| Category: Oncology | ||||||
| 07/20/2023 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $28.75 | General |
| Category: ONCOLOGY | ||||||
| 07/14/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: Oncology | ||||||
| 07/12/2023 | PFIZER INC. | BOSULIF (Drug), BESPONSA, COMIRNATY | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 07/12/2023 | PFIZER INC. | BOSULIF (Drug), BESPONSA, COMIRNATY | Food and Beverage | In-kind items and services | $0.53 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 07/06/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $20.67 | General |
| Category: ONCOLOGY | ||||||
| 06/28/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $22.43 | General |
| Category: Oncology | ||||||
| 06/23/2023 | Amgen Inc. | Nplate (Biological), Vectibix, XGEVA | Food and Beverage | In-kind items and services | $15.23 | General |
| Category: Hematology | ||||||
| 06/22/2023 | PFIZER INC. | BOSULIF (Drug), BESPONSA | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 06/21/2023 | PFIZER INC. | BOSULIF (Drug), BESPONSA | Food and Beverage | In-kind items and services | $0.39 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 06/16/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: Oncology | ||||||
| 06/15/2023 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.59 | General |
| Category: Hematology | ||||||
| 06/07/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 495 | 650 | $82,586 | $44,802 |
| 2022 | 8 | 464 | 773 | $77,803 | $44,922 |
| 2021 | 6 | 472 | 665 | $59,833 | $39,602 |
| 2020 | 7 | 317 | 476 | $51,406 | $16,272 |
Total Patients
1,748
Total Services
2,564
Medicare Billing
$145,598
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 168 | 248 | $34,389 | $19,977 | 58.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 175 | 245 | $21,912 | $10,761 | 49.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $11,203 | $5,853 | 52.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $5,756 | $2,805 | 48.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 23 | $3,956 | $2,741 | 69.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 14 | 14 | $2,054 | $868.60 | 42.3% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 13 | 13 | $1,274 | $752.52 | 59.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 11 | 11 | $770.00 | $602.91 | 78.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 23 | 24 | $1,272 | $441.30 | 34.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 200 | 486 | $40,002 | $24,393 | 61.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 46 | 46 | $11,454 | $6,647 | 58.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 53 | 53 | $10,412 | $5,049 | 48.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 28 | 31 | $3,720 | $2,375 | 63.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 38 | 38 | $4,674 | $2,134 | 45.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 65 | 81 | $4,293 | $2,045 | 47.6% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2022 | 19 | 21 | $2,058 | $1,337 | 65.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 15 | 17 | $1,190 | $941.47 | 79.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 179 | 346 | $24,558 | $16,718 | 68.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 86 | 86 | $14,622 | $9,232 | 63.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 39 | 39 | $8,640 | $5,894 | 68.2% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 100 | 124 | $5,103 | $3,143 | 61.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 42 | 42 | $4,136 | $2,669 | 64.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 26 | 28 | $2,774 | $1,945 | 70.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 131 | 154 | $22,596 | $7,590 | 33.6% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 48 | 48 | $12,348 | $3,772 | 30.5% |
About Dr. Homayoon Shahidi, MD
Dr. Homayoon Shahidi, MD is a Medical Oncology healthcare provider based in Reno, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1295756419.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Homayoon Shahidi, MD has received a total of $5,346 in payments from pharmaceutical and medical device companies, with $374.82 received in 2024. These payments were reported across 258 transactions from 55 companies. The most common payment nature is "Food and Beverage" ($4,628).
As a Medicare-enrolled provider, Shahidi has provided services to 1,748 Medicare beneficiaries, totaling 2,564 services with total Medicare billing of $145,598. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Reno, NV
- Active Since 07/22/2006
- Last Updated 07/31/2020
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1295756419
Products in Payments
- KEYTRUDA (Biological) $276.96
- OPDIVO (Biological) $271.59
- TECENTRIQ (Biological) $220.09
- PROMACTA (Drug) $219.03
- IBRANCE (Drug) $207.44
- REBLOZYL (Biological) $153.75
- Perjeta (Biological) $130.70
- TASIGNA (Drug) $108.62
- Lenvima (Drug) $102.88
- Imbruvica (Drug) $98.03
- LUMAKRAS (Drug) $94.33
- Nplate (Biological) $94.10
- ADCETRIS (Biological) $90.55
- VENCLEXTA (Drug) $85.24
- MONJUVI (Drug) $79.29
- IMBRUVICA (Drug) $77.68
- VERZENIO (Drug) $76.72
- XTANDI (Drug) $74.25
- ERLEADA (Drug) $71.28
- PIQRAY (Drug) $65.53
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.